Bioethics, COVID-19 Vaccine, FDA and Public Health

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioethics

COVID-19 Vaccine

FDA

Public Health

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

SEPTEMBER 28, 2023

Despite having an outsized role in the discovery, development, manufacturing, and procurement of COVID-19 vaccines, therapeutics, and diagnostics, the federal government has generally not exercised any leverage in ensuring fair pricing and affordable access to these essential medical products. In 1989, the U.S.

COVID-19

COVID-19 COVID-19 Vaccine Pharmaceutical Industry Governance

A Timeline of Biden’s Pandemic Response, Part 3: We Have the Tools (Sept. – Dec. 2021)

Bill of Health

JANUARY 7, 2022

Over the summer of 2021, concern grew that the vaccines were not providing the near-perfect protection against symptomatic disease and transmission that had first emboldened the administration to jettison other public health measures. Ultimately, both the FDA and CDC gave their blessing to boosters.

Public Health

Public Health FDA Governance COVID-19 Vaccine

Health Care Compliance Brief

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

A Timeline of Biden’s Pandemic Response, Part 3: We Have the Tools (Sept. – Dec. 2021)

Stay Connected